Syntec Optics (OPTX) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
3 Apr, 2026Executive summary
Q4 2025 marked a turning point with improved manufacturing execution, cost structure alignment, and margin expansion, driving significant growth in adjusted EBITDA and profitability.
Operational inconsistencies in 2024 and early 2025 were addressed, leading to enhanced profitability and execution in Q4.
Positive momentum in defense tech, space optics, and biomedical product lines contributed to growth.
Continued yield and throughput improvements across key programs, with expanded night shift staffing to support scalable production.
Financial highlights
Q4 2025 revenue was $7.5 million, up 2.5% year-over-year and $0.6 million sequentially.
Q4 2025 gross margin nearly doubled to 24% from 13% in Q4 2024 and 12% in Q3 2025, with gross profit up 80% year-over-year to $1.8 million.
Q4 2025 SG&A expense decreased 30% sequentially and 40% year-over-year to $1.5 million.
Q4 2025 adjusted EBITDA rose to $0.9 million, up nearly $1 million versus both prior year and prior quarter.
Full year 2025 net sales were $28.1 million, down $0.4 million from 2024, but gross profit rose 13% to $6.5 million and adjusted EBITDA reached $3.0 million, up 36%.
Earnings per share improved to -0.05 in 2025 from -0.07 in 2024.
Cash provided by operations increased to $0.7 million; cash and available credit totaled $1.1 million at year-end.
Outlook and guidance
Q1 2026 net sales expected below Q4 2025's $7.5 million; Q2 2026 net sales expected above $7.5 million.
2026 growth expected from ramp-up in space optics, AI/data center optics, defense tech, and next-gen communications product lines.
Defense tech product lines anticipated to add net sales in Q2 and beyond.
Expansion in defense tech driven by onshoring tailwinds and new legislation.
Latest events from Syntec Optics
- Vertically integrated optics firm seeks $20M IPO to drive acquisitions and growth amid operational risks.OPTX
Registration filing27 Apr 2026 - Strong H1 2025 profit growth and margin expansion driven by defense, biomedical, and communications.OPTX
Q2 202513 Feb 2026 - Gross margin rose to 29% in H1 2025 as sales and adjusted EBITDA improved year-over-year.OPTX
Q4 202413 Feb 2026 - Q1 2025 net income turned positive on 13% sales growth and improved margins.OPTX
Q1 202513 Feb 2026 - Q3 2025 revenue rose sequentially but margins fell; liquidity improved and Q4 outlook is positive.OPTX
Q3 202512 Feb 2026 - Q2 sales up 12% sequentially, product growth strong, and Q3 outlook robust.OPTX
Q2 20242 Feb 2026 - Q3 sales up 19% year-over-year, but higher costs led to a net loss; Q4 outlook is positive.OPTX
Q3 202413 Jan 2026 - Virtual meeting to vote on directors, auditor, RSUs, and governance amendments; board recommends approval.OPTX
Proxy Filing8 Dec 2025 - Shareholders will vote on director elections, auditor ratification, and RSU grants at the virtual annual meeting.OPTX
Proxy Filing2 Dec 2025